Stem Cell Transplant Complications clinical trials at University of California Health

• A Study of Experimental Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (Mono)

  open to all eligible people

  The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

  at UC Davis

• A Study of RV521 in the Treatment of Adult Subjects With an Upper Respiratory Tract Infection

  open to eligible people ages 18-75

  RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

  at UCLA

• Delirium in Children Undergoing Stem Cell Transplantation

  open to eligible people ages up to 21 years

  Children undergoing stem cell transplants are at risk for delirium, a temporary change in thinking and behavior. This study will define delirium rates, risk factors, and outcomes. Our eventual goal is to reduce delirium in this population.

  at UCSF

• Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

  open to all eligible people

  The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

  at UC Davis UCLA UCSD

Last updated: October 4, 2021